NTHI
NeOnc Technologies Holdings, Inc. Common StockNTHI
NTHI
About: NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").
–
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Research analyst outlook
We haven’t received any recent analyst ratings for NTHI.
Financial journalist opinion
Based on 8 articles about NTHI published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
NeOnc Technologies Global Patent Portfolio Covers Core Pipeline Across All Major Pharmaceutical Markets
-- 176 Patents Issued and Outstanding Reinforces NeOnc's Competitive Position -- CALABASAS, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a biopharmaceutical company focused on the development of novel oncology and neurology therapeutics, today announced that its global patent portfolio totals 176, reinforcing its competitive position.
Neutral
GlobeNewsWire
1 week ago
NeOnc Technologies Holdings, Inc. Expects Full Enrollment in Promising Phase 2a Trial of NEO100-01 for Malignant Gliomas in September
-- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that it expects full enrollment in its Phase 2a clinical trial for its lead therapeutic candidate, NEO100-01 in September. Only six patients remain to complete the trial's 25-patient enrollment target.
Neutral
GlobeNewsWire
1 week ago
NeOnc Technologies Holdings, Inc. Executive Chairman, Amir Heshmatpour, Assumes Expanded Leadership Role as Company's New President
CALABASAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that Executive Chairman Amir Heshmatpour has been appointed to serve as President of the Company. Heshmatpour will retain his role as Executive Chairman, while taking on day-to-day leadership responsibilities to accelerate the Company's strategic and clinical initiatives.
Neutral
GlobeNewsWire
1 week ago
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous system (CNS) cancers and disorders, today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to complete the study's dosing protocol, marking a major milestone in the drug's development timeline.
Neutral
GlobeNewsWire
3 weeks ago
NeOnc Technologies Holdings, Inc. Receives Rare Pediatric Disease Designation for NEO100 in Treatment of Pediatric-Type Diffuse High-Grade Gliomas
WESTLAKE VILLAGE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ Global Market: NTHI), a clinical-stage medical biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to perillyl alcohol (NEO100™) for the treatment of pediatric-type diffuse high-grade gliomas, a serious and life-threatening condition affecting children and adolescents.
Neutral
GlobeNewsWire
3 weeks ago
NeOnc Technologies Expands Global Clinical Trial Network with CBCC Global Research to Accelerate Study of Brain Cancer Treatments
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq Global Market: NTHI), a clinical-stage medical biotechnology company, today announced a strategic partnership with CBCC Global Research (CBCC), a premier full-service clinical research organization (CRO). This collaboration will expand NeOnc's clinical trial capabilities in India, facilitating the advancement of its development-stage neuro-oncology treatment.
Neutral
GlobeNewsWire
3 weeks ago
NeOnc Technologies Appointments the Honorable Jimmy Delshad to its Board of Directors
Delshad adds broad management and financial expertise to the NeOnc team Delshad adds broad management and financial expertise to the NeOnc team
Neutral
GlobeNewsWire
3 weeks ago
NEONC Technologies Holdings, Inc. Appoints Renowned Neurosurgeon Dr. Steven L. Giannotta to its Board of Directors
Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team Dr. Giannotta brings extensive cerebrovascular and cranial base surgery experience and expertise to the NeOnc team
Neutral
Seeking Alpha
3 months ago
U.S. IPO Weekly Recap: 2 Microcaps List As More Small Issuers File For Listings
Two small IPOs listed this week - INLIF and OneConstruction Group. Five issuers and two SPACs submitted initial filings this week. The 2025 IPO market is here, and while there are a few small deals on the calendar, some large names in the pipeline could launch in the week ahead.
Neutral
GlobeNewsWire
6 months ago
NeOnc Technologies Receives Pharma Tech Outlook's Top Drug Delivery Platform Award for 2024
NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook NeOnc's Novel Intranasal Approach to Bypassing the Blood Brain Barrier with Therapeutics for CNS Diseases Featured as Cover Page Story in Recent Edition of Pharma Tech Outlook
Charts implemented using Lightweight Charts™